November 20–21, 2009
New York, New York
The Westin New York at Times Square

Chair:
Corey J. Langer, MD, FACP
University of Pennsylvania
Philadelphia, Pennsylvania
Dear Colleague,

Please join me in New York City this November for the 14th Annual Perspectives in Thoracic Oncology.

14 Years of Exceptional Educational Value
Perspectives in Thoracic Oncology has become the premier source for updates in thoracic oncology; we readily recognize the burgeoning need among thoracic oncology clinicians and researchers for the latest information on the complex biology and treatment of lung cancer. This conference provides a forum to update your knowledge in the field, confirm your current practices, and receive valuable take-home information on exciting new screening and staging modalities, management approaches, and emerging treatment options.

Significant Impact on Clinical Practice
Nearly 200 physicians, nurses, and other healthcare professionals attend Perspectives in Thoracic Oncology annually. Past participants value the scope and depth of the information on disease biology, management, and research presented, and many return year after year for the newest updates.

Distinguished Faculty and Networking Opportunities
In this educational setting, you will have valuable opportunities to interact with your colleagues and learn from renowned faculty, key thought leaders in thoracic oncology, as well as network with the diverse mix of oncologists, surgeons, and pulmonologists who attend.

This fall’s conference, to be held November 20-21, 2009, at the Westin New York at Times Square, promises to be our most exciting meeting yet. I hope to see you there!

Sincerely,
Corey J. Langer, MD, FACP
Chair

Confirmed Faculty

Chandra P. Belani, MD
Penn State Hershey Cancer Institute
Hershey, Pennsylvania

Jeffrey D. Bradley, MD
Washington University School of Medicine
St. Louis, Missouri

Paul A. Bunn, Jr., MD
University of Colorado Cancer Center
Aurora, Colorado

Hak Choy, MD
University of Texas South Western
Dallas, Texas

Roger B. Cohen, MD
Fox Chase Cancer Center
Philadelphia, Pennsylvania

Walter J. Curran, Jr., MD, FACP
Emory Winship Cancer Institute
Atlanta, Georgia

Angela M. Davies, MD, FRCPC
OSI Pharmaceuticals, Inc.
Boulder, Colorado

Jessica S. Donington, MD
Stanford University School of Medicine
Stanford, California

Afshin N. Dowlati, MD
Case Western Reserve University
Cleveland, Ohio

David S. Ettinger, MD, FACP, FCCP
Johns Hopkins University School of Medicine
Baltimore, Maryland

Tracey L. Evans, MD
University of Pennsylvania
Philadelphia, Pennsylvania

Elizabeth Gore, MD
Medical College of Wisconsin
Milwaukee, Wisconsin

Nasser H. Hanna, MD
Indiana University School of Medicine
Indianapolis, Indiana

Karen L. Kelly, MD
The University of Kansas Cancer Center
Kansas City, Kansas

Edward S. Kim, MD
University of Texas MD Anderson Cancer Center
Houston, Texas

Corporate Support

The following companies have provided an educational grant in support of this conference:

GOLD: Genentech BioOncology and OSI Oncology

SILVER: Bristol-Myers Squibb Company

Several options are available to companies interested in supporting this conference. For more information, please contact Imedex at +1 (770) 751 7332, or by email at cme@imedex.com.
Continuing Medical Education

Imedex, LLC is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Imedex, LLC designates this educational activity for a maximum 12.25 of AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Who Should Attend

This educational activity is designed for medical oncologists, radiation oncologists, surgical oncologists, pulmonologists, pathologists, and other healthcare providers involved and/or interested in the diagnosis, treatment, and management of patients with thoracic malignancies.

Objectives

Upon completion of this activity, participants should be able to:

- Describe the evolving epidemiology of lung cancer and comment on the current status of women and lung cancer
- Discuss surgical issues and controversies related to treatment of thoracic cancers
- Evaluate the role of stereotactic radiotherapy and image-guided radiation therapy in non-small cell lung cancer (NSCLC), focusing on the benefits and limitations of each
- Recommend the most appropriate adjuvant therapy regimen for NSCLC, including selecting patients for therapy and predicting benefit
- Outline management strategies for esophageal cancer, mesothelioma, and small cell lung cancer (SCLC)
- Identify controversies in the management of locally advanced NSCLC
- Analyze available and emerging treatment options in advanced NSCLC, including maintenance therapy and third-line therapy and beyond
- Discuss areas of therapeutic neglect in lung cancer and recommend management strategies for pleural effusion, brain metastases, and toxicities from combined modality therapy
- Evaluate the emerging role of targeted therapies and immunomodulators as monotherapy and in combination with established regimens for the treatment of NSCLC
- Comment on the appropriate use of biomarkers guiding the therapeutic decision-making process in patients with NSCLC

Hedy L. Kindler, MD
University of Chicago Medical Center
Chicago, Illinois

Brian E. Lally, MD
University of Miami Miller School of Medicine
Miami, Florida

Corey J. Langer, MD, FACP
University of Pennsylvania
Philadelphia, Pennsylvania

John J. Nemunaitis, MD
Mary Crowley Cancer Research Center
Dallas, Texas

Howard Safran, MD
Miriam Hospital
Providence, Rhode Island

Walter J. Scott, MD, FACS
Fox Chase Cancer Center
Philadelphia, Pennsylvania

Joseph B. Shragar, MD
Stanford University School of Medicine
Stanford, California

Gerard A. Silvestri, MD, MS
Medical University of South Carolina
Charleston, South Carolina

George R. Simon, MD, FACP, FCCP
Fox Chase Cancer Center
Philadelphia, Pennsylvania

Mark Socinski, MD
University of North Carolina
Lineberger Comprehensive Cancer Center
Chapel Hill, North Carolina

Daniel H. Sterman, MD
University of Pennsylvania
Philadelphia, Pennsylvania

Gary M. Strauss, MD, MPH
Tufts Medical Center
Boston, Massachusetts

Michael Unger, MD, FACP, FCCP
Fox Chase Cancer Center
Philadelphia, Pennsylvania

Maria Werner-Wasik, MD
Thomas Jefferson University Hospital
Philadelphia, Pennsylvania

Antoinette J. Wozniak, MD, FACP
Wayne State University
Detroit, Michigan
Scientific Agenda

Friday, November 20, 2009

8:00 am  Welcome
Corey J. Langer, MD, FACP

Session I: Introductory lectures
8:05 am  Keynote lecture: Lung cancer – evolving epidemiology, risk factors, and molecular genetics
Paul A. Bunn, Jr, MD

8:30 am  Women and lung cancer: Is it now epidemic, and should women be treated differently?
Jessica S. Donington, MD

8:55 am  The changing demographics of smoking and its effects during therapy
Angela M. Davies, MD, FRCP

9:15 am  Panel discussion

9:30 am  Break

Session II: Surgery and staging
9:50 am  Case presentation: Ongoing research issues in surgery
More is better
Joseph B. Shrager, MD

Less is better
Walter J. Scott, MD, FACS

10:20 am  Cost-effective staging in NSCLC
Gerard A. Silvestri, MD, MS

10:40 am  Interventional bronchoscopy for the management of endobronchial lesions
Michael Unger, MD, FACP, FCCP

11:00 am  Panel discussion

11:15 am  Lunch

Session III: Radiation oncology for the uninitiated and perpetually perplexed
12:45 pm  V20 and other therapeutic parameters: What are they and how do we accommodate them?
Walter J. Curran, MD, FACP

1:05 pm  Stereotactic radiation: Emerging role in localized lung cancer
Hak Choy, MD

1:25 pm  Image-guided radiation therapy: Therapeutic implications and limitations
Jeffrey D. Bradley, MD

1:45 pm  Is there a role for adjuvant radiotherapy in resected NSCLC?
Brian E. Lally, MD

2:05 pm  Panel discussion

2:15 pm  Break

Session IV: Adjuvant therapy
2:30 pm  Selecting the appropriate patient and the adjuvant therapeutic regimen
Gary M. Strauss, MD, MPH

2:50 pm  Ongoing clinical trials in the adjuvant arena: Where are we heading?
Tracey L. Evans, MD

3:10 pm  Neoadjuvant therapy for NSCLC: When is it useful? When is it not?
Chandra P. Belani, MD

Session V: Special topics in thoracic oncology
3:30 pm  Esophageal cancer
Howard Safran, MD

3:50 pm  Mesothelioma
Hedy L. Kindler, MD

4:10 pm  SCLC: Are we doomed to therapeutic paralysis?
David S. Ettinger, MD

4:30 pm  Discussion

4:45 pm  Adjourn

Saturday, November 21, 2009

8:30 am  Welcome to day two
Corey J. Langer, MD, FACP

Session VI: Advanced NSCLC
8:40 am  First-line treatment for advanced NSCLC: What is the standard?
Antoinette J. Wozniak, MD, FACP

9:05 am  Molecular determination of cytotoxic therapy
George R. Simon, MD, FACP, FCCP

9:25 am  Maintenance therapy in advanced NSCLC: Has its time arrived?
Corey J. Langer, MD, FACP

9:45 am  Third-line therapy and beyond
Nasser H. Hanna, MD

10:10 am  Break
Scientific Agenda (cont’d)

Session VII: Therapeutic neglect in lung cancer
10:30 am Management of pleural effusions  
Daniel H. Sterman, MD
10:50 am Brain metastases: New therapies, new insights  
Elizabeth M. Gore, MD
11:10 am Managing the toxicities of combined modality therapy  
Maria Werner-Wasik, MD
11:30 am Discussion
11:45 am Lunch

Session VIII: Targeted therapies and immunomodulation
1:00 pm Antibodies: Cetuximab, bevacizumab and beyond  
Edward S. Kim, MD
1:20 pm New angiogenesis inhibitors and tyrosine kinase inhibitors in the treatment of NSCLC  
Karen L. Kelley, MD
1:50 pm Vaccines: Are there realistic expectations?  
John J. Nemunaitis, MD
2:10 pm Promising new therapies in NSCLC: HDAC inhibitors; hedgehog inhibitors, TRAIL antibodies, etc.  
Roger B. Cohen, MD
2:30 pm Panel discussion
2:50 pm Break

Session IX: Biomarkers
3:10 pm Debate: Which markers should we use to guide therapy with EGFR inhibitors?  
Biomarkers  
Speaker invited  
Clinical markers  
Mark Socinski, MD
3:50 pm Using biomarkers to predict the efficacy of antiangiogenic agents and other targeted therapies  
Afshin N. Dowlati, MD
4:15 pm Summary and adjournment  
Corey J. Langer, MD, FACP

Please visit www.imedex.com for the most up-to-date agenda and to register.
Registration Form

CONFERENCE REGISTRATION

FIRST NAME ___________________________ LAST NAME ___________________________ MI ___________________________

DEGREE: □ MD □ PhD □ PharmD □ RN □ Other Degree __________________________________________

SPECIALTY: □ Medical Oncology □ Nursing □ Pathology □ Pulmonology □ Radiation Oncology
□ Surgery □ Other __________________________________________

EMAIL ADDRESS __________________________________________

TELEPHONE ___________________________ FAX ___________________________

INSTITUTE ___________________________ DEPARTMENT ___________________________

ADDRESS __________________________________________

CITY ___________________________ STATE / PROVINCE ___________________________

ZIP / POSTAL CODE ___________________________ COUNTRY ___________________________

☐ Check if you require special facilities or assistance and attach a note with specific details and requirements.

REGISTRATION FEES

Note: Only one discount can be applied per registrant

☐ $250 Discounted Payment received by September 22, 2009
☐ $350 Regular Payment received by November 12, 2009
☐ $450 Full/Onsite Payment received after November 12, 2009
☐ -$50 Group discount (Physicians Only)

☐ $99 Nurses/Residents/Students Proof of eligibility must accompany registration

PAYMENT METHOD

Credit card transactions will appear under the name Imedex Inc. on your next statement.

☐ American Express ☐ MasterCard ☐ Visa ☐ Check in the amount of: $_______________________________

Card No. ___________________________ Exp. Date: ________ /__________

Cardholder’s Name: ___________________________________ Signature: _______________________________

To pre-register, registration and payment must be received no later than November 12, 2009. Please register onsite after this date. Contact Imedex at +1 (678) 242 0906 or visit our website at www.imedex.com to ensure that the program is being held as scheduled and to confirm that the meeting is not full.

For registration fees to be refunded, written notice of cancellation must be received at meetings@imedex.com no later than November 12, 2009. The amount of registration fees remitted, minus a $75 administrative charge, will be refunded after the conference. Substitutions are accepted with written notification. No refunds will be made if notice is received after November 12, 2009.
Registration Procedures

To Register: You may register online by November 12, 2009 at www.imedex.com by calling Imedex at +1 (678) 242 0906 or by returning the registration form in this program by mail or fax. If you mail the form, please keep a copy for your records. Registration confirmations will be issued before the meeting.

To qualify for special registration fees, registration and full payment must be received by Imedex by the dates specified.

The Registration and Information Desk at the Westin New York will be staffed:
Friday, November 21 ............... 7:00 am – 5:30 pm
Saturday, November 22 ........... 7:30 am – 5:00 pm

Group Discounts: Each one of multiple registrants from the same institute or practice will receive a $50 discount off the published registration fees, provided all registration forms and payments are received together. Only one discount will apply per physician. Discounts are not available for Nurses/Residents/Students.

Payment: To pre-register, registration and payment must be received no later than November 12, 2009. Please register onsite after this date. Contact Imedex at +1 (678) 242 0906, or visit our website at www.imedex.com to ensure the course is being held as scheduled, and to confirm that the meeting is not full. Registration fees must be remitted by credit card or check. Checks should be payable to Imedex. Attendee is not registered until full payment is received.

Registration Fee Inclusions: Registration fees include admittance to all scientific sessions, conference materials, processing of certificates of attendance or continuing medical education, and all event functions as specified in the program.

Cancellation: For registration fees to be refunded, written notice of cancellation must be received at meetings@imedex.com no later than November 12, 2009. The amount of registration fees remitted, minus a $75 administrative charge, will be refunded after the conference. Substitutions are accepted with written notification. No refunds will be made if notice is received after November 12, 2009.

Imedex does not accept responsibility for covering travel, accommodation, or any other costs incurred by registrants in the rare event that this meeting should be canceled for any reason. Every effort will be made to give reasonable notice in the event of cancellation. The event agenda is subject to change without notice.

Discounted ...................... $250
Payment received by September 22, 2009

Regular ......................... $350
Payment received by November 12, 2009

Full/Onsite: ..................... $450
Payment received after November 12, 2009

Group discount (Physicians only) ............-$50
Cannot be combined with any other discounts

Nurses/Residents/Students ........... $99
Proof of eligibility must accompany registration

Imedex is a brand and assumed name used by Imedex, LLC (hereby referred to as Imedex). Imedex is solely responsible for this agenda’s content. Although Imedex attempts to ensure that the information in our program is accurate and timely, matters and opinions discussed and/or presented with respect to clinical matters are those of the discussion participants only, and not necessarily those of Imedex. Moreover, although Imedex attempts to identify and integrate the most qualified medical professionals in our program, TO THE FULLEST EXTENT PERMITTED BY LAW, IMEDEX EXPRESSLY DISCLAIM ALL WARRANTIES, EITHER EXPRESS OR IMPLIED, STATUTORY OR OTHERWISE, INCLUDING BUT NOT LIMITED TO THE IMPLIED WARRANTIES OF MERCHANTABILITY, NON-INFRINGEMENT OF THIRD PARTIES’ RIGHTS, AND FITNESS FOR A PARTICULAR PURPOSE, WITH RESPECT TO THE CONTENT OR ANY MATERIAL PRESENTED. IMEDEX FURTHER MAKES NO REPRESENTATIONS OR WARRANTIES ABOUT THE ACCURACY, RELIABILITY, COMPLETENESS OR TIMELINESS OF THE CONTENT OR ANY MATERIAL PRESENTED.

In addition, the material presented and related discussions are not intended to be medical advice, and the presentation or discussion of such material is not intended to create and does not establish a physician-patient relationship. Medical advice of any nature should be sought from an individual’s own physician.

Neither Imedex nor any of its subsidiaries or affiliates is affiliated with or formally endorsed by a medical society.

Copyright © 2009 Imedex, LLC. All rights reserved. Reproduction in whole or part is prohibited without prior written consent from Imedex and contributing faculty.
14TH ANNUAL PERSPECTIVES IN Thoracic Oncology

November 20–21, 2009
New York, New York

Praise from your colleagues:
“Very satisfied; Continue current format”
“Superb and excellent conference!”
“Great variety of topics…continue with great work”
“Well run and comprehensive conference”

100% of attendees responding to the onsite survey indicated that they had increased their professional knowledge by attending this conference.

Important Dates:
Discounted Registration Deadline
September 22, 2009

Regular Registration Deadline
November 12, 2009

Presentation Dates
November 20-21, 2009

3 WAYS TO LEARN:

PRINT materials are produced by Imedex for your reference needs

ONLINE products are produced by Imedex in 6 user-friendly formats

LIVE meetings are produced by Imedex in 15 countries

Visit www.imedex.com to learn more